<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302353</url>
  </required_header>
  <id_info>
    <org_study_id>PITEI</org_study_id>
    <secondary_id>2009L01628</secondary_id>
    <nct_id>NCT01302353</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Emulsified Isoflurane</brief_title>
  <official_title>Phase I Trial of Emulsified Isoflurane in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, our primary goal is to investigate the safety of intravenous infusion of
      emulsified isoflurane. In order to protect volunteers, the investigators adopt the modified
      Fibonacci dose-escalation, starting from a very low dose which is derived from the 1/600 of
      acute LD50 in pre-clinic study. The trial will be terminated if half of volunteers develop
      severe adverse event in any dose group or any volunteer develop fatal adverse event in any
      group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>after drug infusion to 24 hours after infusion</time_frame>
    <description>The vital signs include heart rate, cardiac rhythm, blood pressure, respiratory rate, pulse oxygen saturation, body temperature and end-tidal carbon dioxide.
All the parameters are measured at the following time points:
before drug infusion, recorded as baseline;
every one minute, immediately from drug infusion to 15 min after infusion;
every two minutes, from 15 min to 30 min after infusion;
every five minutes, from 30 min to 60 min afeter infusion;
every one hour, from 1 hour to 4 hours after infusion;
8 hours and 24 hours after infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of emulsified isoflurane as an intravenous anesthetics</measure>
    <time_frame>immediate from drug infusion, up to 24 hours after infusion</time_frame>
    <description>This secondary outcome is an observational one only.
The response to verbal command, to pain stimulus; and eyelash reflex are tested.
The orientation and finger-to-nose test are also tested.
The end-tidal partial pressure of isoflurane, observer's assessment of alertness/sedation (modified OAS/S score) and Bispectral index (BIS) are also recored.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Adverse Effect of Intravenous Anesthetics</condition>
  <arm_group>
    <arm_group_label>Arm 1 (0.0024 ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (0.006ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (0.012ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (0.02ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 (0.0301ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 (0.0391ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 (0.0508ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 (0.066ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9 (0.0859ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10 (0.1116ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 11 (0.1451ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 12 (0.1886ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 13 (0.2452ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 14 (0.3188ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 15 (0.4144ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 16 (0.5387ml/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emulsified Isoflurane</intervention_name>
    <arm_group_label>Arm 1 (0.0024 ml/kg)</arm_group_label>
    <arm_group_label>Arm 2 (0.006ml/kg)</arm_group_label>
    <arm_group_label>Arm 3 (0.012ml/kg)</arm_group_label>
    <arm_group_label>Arm 4 (0.02ml/kg)</arm_group_label>
    <arm_group_label>Arm 5 (0.0301ml/kg)</arm_group_label>
    <arm_group_label>Arm 6 (0.0391ml/kg)</arm_group_label>
    <arm_group_label>Arm 7 (0.0508ml/kg)</arm_group_label>
    <arm_group_label>Arm 8 (0.066ml/kg)</arm_group_label>
    <arm_group_label>Arm 9 (0.0859ml/kg)</arm_group_label>
    <arm_group_label>Arm 10 (0.1116ml/kg)</arm_group_label>
    <arm_group_label>Arm 11 (0.1451ml/kg)</arm_group_label>
    <arm_group_label>Arm 12 (0.1886ml/kg)</arm_group_label>
    <arm_group_label>Arm 13 (0.2452ml/kg)</arm_group_label>
    <arm_group_label>Arm 14 (0.3188ml/kg)</arm_group_label>
    <arm_group_label>Arm 15 (0.4144ml/kg)</arm_group_label>
    <arm_group_label>Arm 16 (0.5387ml/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18~45 years old (50:50 male:female) healthy volunteer;

          -  Body Mass Index (BMI) 19~24;

          -  health volunteers assessed by medical history and physical examination

               -  systolic blood pressure between 100~140mmHg;

               -  heart rate between 60~100bpm;

               -  pulse oxygen saturation &gt; 97% when inspiring air and reaching 100% after
                  inspiring 100% oxygen for 5 min;

               -  with normal result for routine lab test, including complete blood count, chemical
                  test, urine test and stool test;

          -  Non-smoker and no history of alcohol or drug abuse;

          -  Fully understand the whole process of this trial and sign the informed consent.

        Exclusion Criteria:

          -  Any history of allergy, especially to isoflurane or intralipid;

          -  Any suspected history of malignant hyperthermia in the volunteer or his/her relatives;

          -  Recent use of a medication with a pronounced effect on the central nervous system or
             any other organ (within 3 month)

          -  Recent participation in other clinical trial (within 1 month)

          -  Any history of difficult airway or suspected difficult airway;

          -  Pregnancy;

          -  Hyperlipidemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Liu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, West China Hospital, Sichuan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Drug Clinical Trial• GCP Center,West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jin Liu</name_title>
    <organization>Department of Anesthesiology, West China Hospital, Sichuan University</organization>
  </responsible_party>
  <keyword>Phase I trial</keyword>
  <keyword>Emulsified Isoflurane</keyword>
  <keyword>Health volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

